{"title":"编辑-肝移植围手术期血清钠的控制:是时候采取更积极的方法了?","authors":"A. Nozari, R. Saidi","doi":"10.2174/1874321801004010020","DOIUrl":null,"url":null,"abstract":"In this issue, Dr. D’Oyley reports a rather provocative approach to the perioperative management of hyponatremia, using data from two patients who underwent orthotopic liver transplantation. The author suggests that the routine administration of intravenous furosemide to induce a supranormal diuresis provides a better intraoperative control of serum sodium levels, which can potentially improve the long-term outcome. Hyponatremia is common in patients with chronic liver disease because of low sodium diets, impaired renal handling of free water, and elevated levels of antidiuretic hormone. It may be exacerbated by aggressive diuretic use and is commonly treated with discontinuation of diuretics combined with free water restriction. Despite the evidence that a major tubular effect of furosemide is to inhibit sodium reabsorption in loops of Henle, it has been shown that the administration of the diuretic may result in a net increase in free water excretion in selected patients [1]. The suggested mechanism for an improved water excretion is through an incomplete osmotic equilibration that is achieved during high rates of flow through collecting ducts. Moreover, furosemide may interfere with proximal tubular reabsorption, resulting in an increased delivery of tubular fluid to diluting sites that are unaffected by the drug, and a net increase in the volume of dilute tubular fluid. Therefore, the proposed approach to administer furosemide during liver transplantation may in selected patients result in better perioperative control of hyponatremia. However, cirrhotic patients who require liver transplantation are severely compromised, and have variable degree of renal impairment, [2] making the response to furesmide very unpredictable. Consequently, routine use of furosemide is currently not advised in these patients because it can lead to a worsening of the hyponatremia or too rapid a correction of","PeriodicalId":272376,"journal":{"name":"The Open Anesthesiology Journal","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2010-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Editorial - Perioperative Control of Serum Sodium for Liver Transplantation: Time for a More Aggressive Approach?\",\"authors\":\"A. Nozari, R. Saidi\",\"doi\":\"10.2174/1874321801004010020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In this issue, Dr. D’Oyley reports a rather provocative approach to the perioperative management of hyponatremia, using data from two patients who underwent orthotopic liver transplantation. The author suggests that the routine administration of intravenous furosemide to induce a supranormal diuresis provides a better intraoperative control of serum sodium levels, which can potentially improve the long-term outcome. Hyponatremia is common in patients with chronic liver disease because of low sodium diets, impaired renal handling of free water, and elevated levels of antidiuretic hormone. It may be exacerbated by aggressive diuretic use and is commonly treated with discontinuation of diuretics combined with free water restriction. Despite the evidence that a major tubular effect of furosemide is to inhibit sodium reabsorption in loops of Henle, it has been shown that the administration of the diuretic may result in a net increase in free water excretion in selected patients [1]. The suggested mechanism for an improved water excretion is through an incomplete osmotic equilibration that is achieved during high rates of flow through collecting ducts. Moreover, furosemide may interfere with proximal tubular reabsorption, resulting in an increased delivery of tubular fluid to diluting sites that are unaffected by the drug, and a net increase in the volume of dilute tubular fluid. Therefore, the proposed approach to administer furosemide during liver transplantation may in selected patients result in better perioperative control of hyponatremia. However, cirrhotic patients who require liver transplantation are severely compromised, and have variable degree of renal impairment, [2] making the response to furesmide very unpredictable. Consequently, routine use of furosemide is currently not advised in these patients because it can lead to a worsening of the hyponatremia or too rapid a correction of\",\"PeriodicalId\":272376,\"journal\":{\"name\":\"The Open Anesthesiology Journal\",\"volume\":\"14 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2010-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Open Anesthesiology Journal\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1874321801004010020\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Open Anesthesiology Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1874321801004010020","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
在本期杂志中,Dr. D 'Oyley报道了一种颇具争议的低钠血症围手术期治疗方法,使用了两名接受原位肝移植的患者的数据。作者建议,常规静脉滴注速尿诱导异常利尿可以更好地控制术中血清钠水平,从而有可能改善长期预后。低钠血症常见于慢性肝病患者,原因是低钠饮食、肾脏对游离水的处理受损以及抗利尿激素水平升高。积极使用利尿剂可能会加重,通常通过停用利尿剂并限制自由水来治疗。尽管有证据表明速尿的主要管状作用是抑制Henle袢中的钠重吸收,但也有研究表明,在某些患者中,使用该利尿剂可能导致游离水排泄的净增加[1]。建议的改善水排泄的机制是通过不完全渗透平衡,这是在通过收集管的高流速中实现的。此外,速尿可能干扰近端肾小管重吸收,导致肾小管液体向不受药物影响的稀释部位的输送增加,稀释后肾小管液体的净体积增加。因此,建议在肝移植期间给予呋塞米的方法可能会在选定的患者中更好地控制低钠血症的围手术期。然而,需要肝移植的肝硬化患者严重受损,并有不同程度的肾脏损害[2],使得对呋昔胺的反应非常不可预测。因此,目前不建议这些患者常规使用速尿,因为它可能导致低钠血症恶化或纠正过快
Editorial - Perioperative Control of Serum Sodium for Liver Transplantation: Time for a More Aggressive Approach?
In this issue, Dr. D’Oyley reports a rather provocative approach to the perioperative management of hyponatremia, using data from two patients who underwent orthotopic liver transplantation. The author suggests that the routine administration of intravenous furosemide to induce a supranormal diuresis provides a better intraoperative control of serum sodium levels, which can potentially improve the long-term outcome. Hyponatremia is common in patients with chronic liver disease because of low sodium diets, impaired renal handling of free water, and elevated levels of antidiuretic hormone. It may be exacerbated by aggressive diuretic use and is commonly treated with discontinuation of diuretics combined with free water restriction. Despite the evidence that a major tubular effect of furosemide is to inhibit sodium reabsorption in loops of Henle, it has been shown that the administration of the diuretic may result in a net increase in free water excretion in selected patients [1]. The suggested mechanism for an improved water excretion is through an incomplete osmotic equilibration that is achieved during high rates of flow through collecting ducts. Moreover, furosemide may interfere with proximal tubular reabsorption, resulting in an increased delivery of tubular fluid to diluting sites that are unaffected by the drug, and a net increase in the volume of dilute tubular fluid. Therefore, the proposed approach to administer furosemide during liver transplantation may in selected patients result in better perioperative control of hyponatremia. However, cirrhotic patients who require liver transplantation are severely compromised, and have variable degree of renal impairment, [2] making the response to furesmide very unpredictable. Consequently, routine use of furosemide is currently not advised in these patients because it can lead to a worsening of the hyponatremia or too rapid a correction of